retatrutide clinical trial results 2025 Eli Lilly infiltrates anti-obesity market as Phase III for begins Retatrutide vs Ozempic: Clinical Trial

The SURMOUNT-4 trial found over 50 percent of tirzepatide weight loss rebounded over 52 weeks

Any potential Ozempic settlement would likely depend on the severity of the injury, the supporting medical evidence, and the specific facts of each plaintiffs case

A phase 3 programme evaluating retatrutide across multiple populations including adults with obesity, adults with type 2 diabetes, and individuals with obesity-related comorbidities is under way

Insert the needle into the Retatrutide vial, aiming at the glass wall rather than directly at the powder

The most important factor is consistency injecting on the same day and roughly the same time each week

Since higher-dose formulations of oral and subcutaneous semaglutide are under development, it needs to be seen if they will be approved as anti-obesity drugs [34]